https://m2.mtmt.hu/ hun 2026-09-22 04:40 JournalArticle 36144825 VALIDATED true 0 false 2026-09-08T09:06:40.630+0000 2026-01-19T09:48:05.156+0000 2025-05-16T09:08:58.984+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 2026-07-11T06:16:04.416+0000 2025-06-18T12:06:02.603+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Herwig, Melissa true true /api/journal/10011378 REVIEWED CARDIOVASCULAR DIABETOLOGY 1475-2840 1475-2840 true false 10011378 false 10011378 true 1475-2840 1475-2840 Journal FOREIGN 24 1 203 203 20 2025 Funding 2052978 /api/funding/2052978 National Research, Development and Innovation Office (NKFIH) of Hungary(FK134751) false true Funding 2052979 /api/funding/2052979 (TKP2021-EGA) false true Funding 2053574 /api/funding/2053574 Nemzeti Kardiovaszkuláris Laboratórium(RRF-2.3.1-21-2022-00003) Támogató: NKFIH false true true true 2025 true true true false true false GOLD 2026-09-08 false http://www.cardiab.com/ 16 0 16 14 1 16 16 16 14 16 16 14 14 14 2 0 16 14 16 14 0 29 29 Folyóiratcikk Journal Article 24 16 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 6 5 6 5 2026 0 10 9 10 9 D1 false false false false 2025-05-15T09:11:52.494+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); HCEMM- SE Kardiovaszkuláris Komorbiditások Kuta... (SE / AOK / I / FFI); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI) 5 20 4 22 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 126552917 /api/authorship/126552917 Herwig, Melissa 1 0.045454547 true false false Herwig Melissa true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552918 /api/authorship/126552918 Sieme, Marcel 2 0.045454547 false false false Sieme Marcel true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552919 /api/authorship/126552919 Kovács, Andrea [Kovács, Andrea (hisztológia, immu...), szerző] Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI) 3 0.045454547 false false false Author 10091976 /api/author/10091976 Kovács Andrea (hisztológia, immunológia, kardiológia) Kovács Andrea true true Kovács Andrea true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552920 /api/authorship/126552920 Khan, Muchtiar 4 0.045454547 false false false Khan Muchtiar true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552921 /api/authorship/126552921 Mügge, Andreas 5 0.045454547 false false false Mügge Andreas true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552922 /api/authorship/126552922 Schmidt, Wolfgang E. 6 0.045454547 false false false Schmidt Wolfgang E. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552923 /api/authorship/126552923 Elci, Ferhat 7 0.045454547 false false false Elci Ferhat true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552924 /api/authorship/126552924 Sasidharan, Shan [Sasidharan, Shan (farmakologia), szerző] HCEMM- SE Kardiovaszkuláris Komorbiditások Kuta... (SE / AOK / I / FFI); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 8 0.045 false false false Author 10091267 /api/author/10091267 Sasidharan Shan (farmakologia) Sasidharan Shan true true Sasidharan Shan true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552925 /api/authorship/126552925 Haldenwang, Peter 9 0.045454547 false false false Haldenwang Peter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552926 /api/authorship/126552926 Wintrich, Jan 10 0.045454547 false false false Wintrich Jan true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552927 /api/authorship/126552927 Sasko, Benjamin 11 0.045454547 false false false Sasko Benjamin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552928 /api/authorship/126552928 Akin, Ibrahim 12 0.045454547 false false false Akin Ibrahim true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552929 /api/authorship/126552929 Domokos, Máthé 13 0.045454547 false false false Domokos Máthé true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552930 /api/authorship/126552930 Paneni, Francesco 14 0.045454547 false false false Paneni Francesco true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552931 /api/authorship/126552931 El-Battrawy, Ibrahim 15 0.045454547 false false false El-Battrawy Ibrahim true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552932 /api/authorship/126552932 Varga, Zoltán V. [Varga, Zoltán (kardiovaszkuláris...), szerző] HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 16 0.045 false false false Author 10028393 /api/author/10028393 Varga Zoltán (kardiovaszkuláris kutatás) Varga Zoltán true 10028393 true Varga Zoltán V. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552933 /api/authorship/126552933 Saraiva, Francisca 17 0.045454547 false false false Saraiva Francisca true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552934 /api/authorship/126552934 Leite-Moreira, Adelino F. 18 0.045454547 false false false Leite-Moreira Adelino F. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552935 /api/authorship/126552935 Ferdinandy, Péter [Ferdinandy, Péter (Farmakológia, mol...), szerző] Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 19 0.045 false false false Author 10010125 /api/author/10010125 Ferdinandy Péter (Farmakológia, molekuláris medicina) Ferdinandy Péter true 10010125 true Ferdinandy Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552936 /api/authorship/126552936 van Heerebeek, Loek 20 0.045454547 false false false van Heerebeek Loek true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552937 /api/authorship/126552937 Falcão-Pires, Inês 21 0.045454547 false false false Falcão-Pires Inês true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126552938 /api/authorship/126552938 Hamdani, Nazha ✉ [Hamdani, Nazha (Medicine), szerző] HCEMM- SE Kardiovaszkuláris Komorbiditások Kuta... (SE / AOK / I / FFI); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 22 0.045 false true true Author 10086357 /api/author/10086357 Hamdani Nazha (Medicine) Hamdani Nazha true true Hamdani Nazha true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 29376636 /api/publicationidentifier/29376636 DOI: 10.1186/s12933-025-02748-y PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1186/s12933-025-02748-y https://doi.org/10.1186/s12933-025-02748-y false true PublicationIdentifier 29412746 /api/publicationidentifier/29412746 WoS: 001487788300001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001487788300001 https://www.webofscience.com/wos/woscc/full-record/001487788300001 false true PublicationIdentifier 29400270 /api/publicationidentifier/29400270 Scopus: 105004922757 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105004922757 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105004922757 false true PublicationIdentifier 29376637 /api/publicationidentifier/29376637 PubMed: 40361188 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 40361188 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40361188&dopt=Abstract false true PublicationIdentifier 31184906 /api/publicationidentifier/31184906 Egyéb URL: https://cardiab.biomedcentral.com/articles/10.1186/s12933-025-02748-y PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true IDENTICAL https://cardiab.biomedcentral.com/articles/10.1186/s12933-025-02748-y https://cardiab.biomedcentral.com/articles/10.1186/s12933-025-02748-y false true Classification 12197 /api/classification/12197 Gyógyszerészet, farmakogenomika, gyógyszerkutatás és tervezés, gyógyszeres kezelés true true SjrRating 11563296 /api/sjrrating/11563296 sjr:D1 (2025) Scopus - Cardiology and Cardiovascular Medicine CARDIOVASCULAR DIABETOLOGY 1475-2840 1475-2840 10 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2705 /api/classificationexternal/2705 Scopus - Cardiology and Cardiovascular Medicine true 2705 true D1 DIRECT true true Reference 65850238 /api/reference/65850238 1. Mourino-Alvarez L, Corbacho-Alonso N, Sastre-Oliva T, Corros-Vicente C, Solis J, Tejerina T, et al. Diabetes mellitus and its implications in aortic stenosis patients. Int J Mol Sci. 2021;22:6212., DOI: 10.3390/ijms22126212 1 10.3390/ijms22126212 false true Reference 65850239 /api/reference/65850239 2. Kontogeorgos SM, Rosengren A, Zverkova Sandstrom T, Lindgren M. Progression of aortic stenosis in patients with diabetes mellitus type 2 compared with matched controls. Eur Heart J. 2024;45:ehae666-1798., DOI: 10.1093/eurheartj/ehae666.1798 2 10.1093/eurheartj/ehae666.1798 false true Reference 65850240 /api/reference/65850240 3. Natorska J, Wypasek E, Grudzień G, Sobczyk D, Marek G, Filip G, et al. Does diabetes accelerate the progression of aortic stenosis through enhanced inflammatory response within aortic valves? Inflammation. 2012;35:834–40., DOI: 10.1007/s10753-011-9384-7 3 10.1007/s10753-011-9384-7 false true Reference 65850241 /api/reference/65850241 4. Kopytek M, Mazur P, Ząbczyk M, Undas A, Natorska J. Diabetes concomitant to aortic stenosis is associated with increased expression of NF-κB and more pronounced valve calcification. Diabetologia. 2021;64:2562–74., DOI: 10.1007/s00125-021-05545-w 4 10.1007/s00125-021-05545-w false true Reference 65850242 /api/reference/65850242 5. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Peña-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol. 2008;52:843–50., DOI: 10.1016/j.jacc.2008.05.043 5 10.1016/j.jacc.2008.05.043 false true Reference 65850243 /api/reference/65850243 6. Wada S, Sugioka K, Naruko T, Kato Y, Shibata T, Inoue T, et al. Relationship between oxidative stress and aortic valve stenosis in humans: an immunohistochemical study. Osaka City Med J. 2013;59:61–7. 6 false true Reference 65850244 /api/reference/65850244 7. Mahmod M, Francis JM, Pal N, Lewis A, Dass S, De Silva R, et al. Myocardial perfusion and oxygenation are impaired during stress in severe aortic stenosis and correlate with impaired energetics and subclinical left ventricular dysfunction. J Cardiovasc Magn Reson. 2014;16:29., DOI: 10.1186/1532-429X-16-29 7 10.1186/1532-429X-16-29 false true Reference 65850245 /api/reference/65850245 8. Lindman BR, Arnold SV, Madrazo JA, Zajarias A, Johnson SN, Pérez JE, et al. The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis. Circ Heart Fail. 2011;4:286–92., DOI: 10.1161/CIRCHEARTFAILURE.110.960039 8 10.1161/CIRCHEARTFAILURE.110.960039 false true Reference 65850246 /api/reference/65850246 9. Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000;101:2271–6., DOI: 10.1161/01.CIR.101.19.2271 9 10.1161/01.CIR.101.19.2271 false true Reference 65850247 /api/reference/65850247 10. Van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, et al. Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117:43–51., DOI: 10.1161/CIRCULATIONAHA.107.728550 10 10.1161/CIRCULATIONAHA.107.728550 false true Reference 65850248 /api/reference/65850248 11. Hopf AE, Andresen C, Kötter S, Isić M, Ulrich K, Sahin S, et al. Diabetes-induced cardiomyocyte passive stiffening is caused by impaired insulin-dependent titin modification and can be modulated by neuregulin-1. Circ Res. 2018;123:342–55., DOI: 10.1161/CIRCRESAHA.117.312166 11 10.1161/CIRCRESAHA.117.312166 false true Reference 65850249 /api/reference/65850249 12. Falcão-Pires I, Hamdani N, Borbély A, Gavina C, Schalkwijk CG, Van Der Velden J, et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation. 2011;124:1151–9., DOI: 10.1161/CIRCULATIONAHA.111.025270 12 10.1161/CIRCULATIONAHA.111.025270 false true Reference 65850250 /api/reference/65850250 13. Van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MPV, Bronzwaer JGF, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830–9., DOI: 10.1161/CIRCULATIONAHA.111.076075 13 10.1161/CIRCULATIONAHA.111.076075 false true Reference 65850251 /api/reference/65850251 14. Hamdani N, Bishu KG, Von Frieling-Salewsky M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res. 2013;97:464–71., DOI: 10.1093/cvr/cvs353 14 10.1093/cvr/cvs353 false true Reference 65850252 /api/reference/65850252 15. Kolijn D, Pabel S, Tian Y, Lódi M, Herwig M, Carrizzo A, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovasc Res. 2021;117:495–507., DOI: 10.1093/cvr/cvaa123 15 10.1093/cvr/cvaa123 false true Reference 65850253 /api/reference/65850253 16. Kovács Á, Zhazykbayeva S, Herwig M, Fülöp G, Csípő T, Oláh N, et al. Sex-specific cardiovascular remodeling leads to a divergent sex-dependent development of heart failure in aged hypertensive rats. GeroScience. 2024;46:4543–61., DOI: 10.1007/s11357-024-01160-w 16 10.1007/s11357-024-01160-w false true Reference 65850254 /api/reference/65850254 17. Hassoun R, Budde H, Zhazykbayeva S, Herwig M, Sieme M, Delalat S, et al. Stress activated signalling impaired protein quality control pathways in human hypertrophic cardiomyopathy. Int J Cardiol. 2021;344:160–9., DOI: 10.1016/j.ijcard.2021.09.009 17 10.1016/j.ijcard.2021.09.009 false true Reference 65850255 /api/reference/65850255 18. Kovács Á, Herwig M, Budde H, Delalat S, Kolijn D, Bódi B, et al. Interventricular differences of signaling pathways-mediated regulation of cardiomyocyte function in response to high oxidative stress in the post-ischemic failing rat heart. Antioxidants. 2021;10:964., DOI: 10.3390/antiox10060964 18 10.3390/antiox10060964 false true Reference 65850256 /api/reference/65850256 19. Kolijn D, Kovács Á, Herwig M, Lódi M, Sieme M, Alhaj A, et al. Enhanced cardiomyocyte function in hypertensive rats with diastolic dysfunction and human heart failure patients after acute treatment with soluble guanylyl cyclase (sGC) activator. Front Physiol. 2020;11:345., DOI: 10.3389/fphys.2020.00345 19 10.3389/fphys.2020.00345 false true Reference 65850257 /api/reference/65850257 20. Hamdani N, Franssen C, Lourenço A, Falca o-Pires I, Fontoura D, Leite S, et al. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Hear Fail. 2013;6:1239–49., DOI: 10.1161/CIRCHEARTFAILURE.113.000539 20 10.1161/CIRCHEARTFAILURE.113.000539 false true Reference 65850258 /api/reference/65850258 21. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4:312–24., DOI: 10.1016/j.jchf.2015.10.007 21 10.1016/j.jchf.2015.10.007 false true Reference 65850259 /api/reference/65850259 22. Zhazykbayeva S, Pabel S, Mügge A, Sossalla S, Hamdani N. The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases. Biophys Rev. 2020;12:947., DOI: 10.1007/s12551-020-00742-0 22 10.1007/s12551-020-00742-0 false true Reference 65850260 /api/reference/65850260 23. Zhazykbayeva S, Hassoun R, Herwig M, Budde H, Kovács Á, Mannherz HG, et al. Oxidative stress and inflammation distinctly drive molecular mechanisms of diastolic dysfunction and remodeling in female and male heart failure with preserved ejection fraction rats. Front Cardiovasc Med. 2023;10:1157398., DOI: 10.3389/fcvm.2023.1157398 23 10.3389/fcvm.2023.1157398 false true Reference 65850261 /api/reference/65850261 24. Alegre-Cebollada J, Kosuri P, Giganti D, Eckels E, Rivas-Pardo JA, Hamdani N, et al. S-glutathionylation of cryptic cysteines enhances titin elasticity by blocking protein folding. Cell. 2014;156:1235–46., DOI: 10.1016/j.cell.2014.01.056 24 10.1016/j.cell.2014.01.056 false true Reference 65850262 /api/reference/65850262 25. Breitkreuz M, Hamdani N. A change of heart: Oxidative stress in governing muscle function? Biophys Rev. 2015;7:321–41., DOI: 10.1007/s12551-015-0175-5 25 10.1007/s12551-015-0175-5 false true Reference 65850263 /api/reference/65850263 26. Loescher CM, Breitkreuz M, Li Y, Nickel A, Unger A, Dietl A, et al. Regulation of titin-based cardiac stiffness by unfolded domain oxidation (UnDOx). Proc Natl Acad Sci USA. 2020;117:24545–56., DOI: 10.1073/pnas.2004900117 26 10.1073/pnas.2004900117 false true Reference 65850264 /api/reference/65850264 27. Budde H, Hassoun R, Tangos M, Zhazykbayeva S, Herwig M, Varatnitskaya M, et al. The interplay between S-glutathionylation and phosphorylation of cardiac troponin I and myosin binding protein C in end-stage human failing hearts. Antioxidants. 2021;10:1134., DOI: 10.3390/antiox10071134 27 10.3390/antiox10071134 false true Reference 65850265 /api/reference/65850265 28. Lamberts RR, Onderwater G, Hamdani N, Vreden MJA, Steenhuisen J, Eringa EC, et al. Reactive oxygen species-induced stimulation of 5’amp-activated protein kinase mediates sevoflurane-induced cardioprotection. Circulation. 2009;120:S10–5., DOI: 10.1161/CIRCULATIONAHA.108.828426 28 10.1161/CIRCULATIONAHA.108.828426 false true Reference 65850266 /api/reference/65850266 29. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632., DOI: 10.1093/eurheartj/ehab395 29 10.1093/eurheartj/ehab395 false true Reference 65850267 /api/reference/65850267 30. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323., DOI: 10.1093/eurheartj/ehz486 30 10.1093/eurheartj/ehz486 false true Reference 65850268 /api/reference/65850268 31. Erratum: Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:412., DOI: 10.1093/ehjci/jew041 31 10.1093/ehjci/jew041 false true Reference 65850269 /api/reference/65850269 32. Hamdani N, Krysiak J, Kreusser MM, Neef S, Dos Remedios CG, Maier LS, et al. Crucial role for Ca2+/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res. 2013;112:664–74., DOI: 10.1161/CIRCRESAHA.111.300105 32 10.1161/CIRCRESAHA.111.300105 false true Reference 65850270 /api/reference/65850270 33. Herwig M, Begovic M, Budde H, Delalat S, Zhazykbayeva S, Sieme M, et al. Protein kinase D plays a crucial role in maintaining cardiac homeostasis by regulating post-translational modifications of myofilament proteins. Int J Mol Sci. 2024;25:2790., DOI: 10.3390/ijms25052790 33 10.3390/ijms25052790 false true Reference 65850271 /api/reference/65850271 34. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. 1999;22:1186–90., DOI: 10.2337/diacare.22.7.1186 34 10.2337/diacare.22.7.1186 false true Reference 65850272 /api/reference/65850272 35. Krüger M, Linke WA. Protein kinase-A phosphorylates titin in human heart muscle and reduces myofibrillar passive tension. J Muscle Res Cell Motil. 2006;27:435–44., DOI: 10.1007/s10974-006-9090-5 35 10.1007/s10974-006-9090-5 false true Reference 65850273 /api/reference/65850273 36. Kamalesh M, Ng C, El Masry H, Eckert G, Sawada S. Does diabetes accelerate progression of calcific aortic stenosis? Eur J Echocardiogr. 2009;10:723–5., DOI: 10.1093/ejechocard/jep048 36 10.1093/ejechocard/jep048 false true Reference 65850274 /api/reference/65850274 37. Larsson SC, Wallin A, Håkansson N, Stackelberg O, Bäck M, Wolk A. Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. Int J Cardiol. 2018;262:66–70., DOI: 10.1016/j.ijcard.2018.03.099 37 10.1016/j.ijcard.2018.03.099 false true Reference 65850275 /api/reference/65850275 38. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693–5., DOI: 10.1016/S0002-9149(01)01821-5 38 10.1016/S0002-9149(01)01821-5 false true Reference 65850276 /api/reference/65850276 39. Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM, Probstfield JL, et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Circulation. 2006;113:2113–9., DOI: 10.1161/CIRCULATIONAHA.105.598086 39 10.1161/CIRCULATIONAHA.105.598086 false true Reference 65850277 /api/reference/65850277 40. Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2019;20:247–60., DOI: 10.1016/j.redox.2018.09.025 40 10.1016/j.redox.2018.09.025 false true Reference 65850278 /api/reference/65850278 41. Kopytek M, Zabczyk M, Mazur P, Undas A, Natorska J. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes. Cardiovasc Diabetol. 2020;19:1–12., DOI: 10.1186/s12933-020-01068-7 41 10.1186/s12933-020-01068-7 false true Reference 65850279 /api/reference/65850279 42. Wang Y, Zhong J, Zhang X, Liu Z, Yang Y, Gong Q, et al. The role of HMGB1 in the pathogenesis of type 2 diabetes. J Diabetes Res. 2016;2016:2543268., DOI: 10.1155/2016/2543268 42 10.1155/2016/2543268 false true Reference 65850280 /api/reference/65850280 43. Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care. 2010;33:861–8., DOI: 10.2337/dc09-1799 43 10.2337/dc09-1799 false true Reference 65850281 /api/reference/65850281 44. Škrha J, Kalousová M, Švarcová J, Muravská A, Kvasnička J, Landová L, et al. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120:277–81., DOI: 10.1055/s-0031-1283161 44 10.1055/s-0031-1283161 false true Reference 65850282 /api/reference/65850282 45. Sharma A, Tate M, Mathew G, Vince JE, Ritchie RH, De Haan JB. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front Physiol. 2018;9:331431., DOI: 10.3389/fphys.2018.00114 45 10.3389/fphys.2018.00114 false true Reference 65850283 /api/reference/65850283 46. Lee HJ, Park CS, Lee S, Park JB, Kim HK, Park SJ, et al. Systemic proinflammatory−profibrotic response in aortic stenosis patients with diabetes and its relationship with myocardial remodeling and clinical outcome. Cardiovasc Diabetol. 2023;22:30., DOI: 10.1186/s12933-023-01763-1 46 10.1186/s12933-023-01763-1 false true Reference 65850284 /api/reference/65850284 47. Calabrese V, Cornelius C, Leso V, Trovato-Salinaro A, Ventimiglia B, Cavallaro M, et al. Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. Biochim Biophys Acta Mol Basis Dis. 2012;1822:729–36., DOI: 10.1016/j.bbadis.2011.12.003 47 10.1016/j.bbadis.2011.12.003 false true Reference 65850285 /api/reference/65850285 48. Leoncini G, Signorello MG, Piana A, Carrubba M, Armani U. Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. Thromb Res. 1997;86:153–60., DOI: 10.1016/S0049-3848(97)00058-3 48 10.1016/S0049-3848(97)00058-3 false true Reference 65850286 /api/reference/65850286 49. de Souza BA, Graves DT, de Melo Loureiro AP, Júnior CR, Corbi SCT, Frizzera F, et al. Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients. J Diabetes Complicat. 2016;30:1593–9., DOI: 10.1016/j.jdiacomp.2016.07.011 49 10.1016/j.jdiacomp.2016.07.011 false true Reference 65850287 /api/reference/65850287 50. Schilling JD. The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise. Antioxid Redox Signal. 2015;22:1515–26., DOI: 10.1089/ars.2015.6294 50 10.1089/ars.2015.6294 false true Reference 65850288 /api/reference/65850288 51. Grützner A, Garcia-Manyes S, Kötter S, Badilla CL, Fernandez JM, Linke WA. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J. 2009;97:825–34., DOI: 10.1016/j.bpj.2009.05.037 51 10.1016/j.bpj.2009.05.037 false true Reference 65850289 /api/reference/65850289 52. Giganti D, Yan K, Badilla CL, Fernandez JM, Alegre-Cebollada J. Disulfide isomerization reactions in titin immunoglobulin domains enable a mode of protein elasticity. Nat Commun. 2018;9(1):1–11., DOI: 10.1038/s41467-017-02528-7 52 10.1038/s41467-017-02528-7 false true Reference 65850290 /api/reference/65850290 53. Gömöri K, Herwig M, Budde H, Hassoun R, Mostafi N, Zhazykbayeva S, et al. Ca2+/calmodulin-dependent protein kinase II and protein kinase G oxidation contributes to impaired sarcomeric proteins in hypertrophy model. ESC Hear Fail. 2022;9:2585–600., DOI: 10.1002/ehf2.13973 53 10.1002/ehf2.13973 false true Reference 65850291 /api/reference/65850291 54. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597–605., DOI: 10.1161/CIRCULATIONAHA.106.621854 54 10.1161/CIRCULATIONAHA.106.621854 false true Reference 65850292 /api/reference/65850292 55. Velagic A, Qin C, Woodman OL, Horowitz JD, Ritchie RH, Kemp-Harper BK. Nitroxyl: A novel strategy to circumvent diabetes associated impairments in nitric oxide signaling. Front Pharmacol. 2020;11:539513., DOI: 10.3389/fphar.2020.00727 55 10.3389/fphar.2020.00727 false true Reference 65850293 /api/reference/65850293 56. Kong Q, Blanton RM. Protein kinase GI and heart failure shifting focus from vascular unloading to direct myocardial antiremodeling effects. Circ Hear Fail. 2013;6:1268–83., DOI: 10.1161/CIRCHEARTFAILURE.113.000575 56 10.1161/CIRCHEARTFAILURE.113.000575 false true Reference 65850294 /api/reference/65850294 57. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122:216–38., DOI: 10.1016/j.pharmthera.2009.02.009 57 10.1016/j.pharmthera.2009.02.009 false true Reference 65850295 /api/reference/65850295 58. Li Z, LaPenna KB, Gehred ND, Yu X, Tang WHW, Ron JE, et al. Dysregulation of nitrosylation dynamics promotes nitrosative stress and contributes to cardiometabolic heart failure with preserved ejection fraction. bioRxiv Prepr Serv Biol. 2024., DOI: 10.1101/2024.12.20.629549 58 10.1101/2024.12.20.629549 false true Reference 65850296 /api/reference/65850296 59. Linke WA, Hamdani N. Gigantic business: titin properties and function through thick and thin. Circ Res. 2014;114:1052–68., DOI: 10.1161/CIRCRESAHA.114.301286 59 10.1161/CIRCRESAHA.114.301286 false true Reference 65850297 /api/reference/65850297 60. Van Heerebeek L, Borbély A, Niessen HWM, Bronzwaer JGF, Van Der Velden J, Stienen GJM, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966–73., DOI: 10.1161/CIRCULATIONAHA.105.587519 60 10.1161/CIRCULATIONAHA.105.587519 false true Reference 65850298 /api/reference/65850298 61. Borbély A, Falcao-Pires I, Van Heerebeek L, Hamdani N, Édes I, Gavina C, et al. Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res. 2009;104:780–6., DOI: 10.1161/CIRCRESAHA.108.193326 61 10.1161/CIRCRESAHA.108.193326 false true Reference 65850299 /api/reference/65850299 62. Williams L, Howell N, Pagano D, Andreka P, Vertesaljai M, Pecor T, et al. Titin isoform expression in aortic stenosis. Clin Sci. 2009;117:237–42., DOI: 10.1042/CS20080248 62 10.1042/CS20080248 false true Reference 65850300 /api/reference/65850300 63. Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM, et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res. 2009;104:87–94., DOI: 10.1161/CIRCRESAHA.108.184408 63 10.1161/CIRCRESAHA.108.184408 false true Reference 65850301 /api/reference/65850301 64. Hidalgo C, Hudson B, Bogomolovas J, Zhu Y, Anderson B, Greaser M, et al. PKC phosphorylation of titin’s PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ Res. 2009;105:631–8., DOI: 10.1161/CIRCRESAHA.109.198465 64 10.1161/CIRCRESAHA.109.198465 false true Reference 65850302 /api/reference/65850302 65. Hidalgo CG, Chung CS, Saripalli C, Methawasin M, Hutchinson KR, Tsaprailis G, et al. The multifunctional Ca2+/calmodulin-dependent protein kinase II delta (CaMKIIδ) phosphorylates cardiac titin’s spring elements. J Mol Cell Cardiol. 2013;54:90–7., DOI: 10.1016/j.yjmcc.2012.11.012 65 10.1016/j.yjmcc.2012.11.012 false true Reference 65850303 /api/reference/65850303 66. Pabel S, Wagner S, Bollenberg H, Bengel P, Kovács Á, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20:1690–700., DOI: 10.1002/ejhf.1328 66 10.1002/ejhf.1328 false true Reference 65850304 /api/reference/65850304 67. Matsuda K, Mitsuo H, Nishijima T, Uchiyama H, Nita T, Matsunaga S, et al. Acute dapagliflozin administration ameliorates cardiac surgery-associated acute kidney injury in a rabbit model. Circ J. 2024;88:1488–98., DOI: 10.1253/circj.CJ-23-0864 67 10.1253/circj.CJ-23-0864 false true Reference 65850305 /api/reference/65850305 68. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–24., DOI: 10.1056/NEJMoa2022190 68 10.1056/NEJMoa2022190 false true Reference 65850306 /api/reference/65850306 69. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61., DOI: 10.1056/NEJMoa2107038 69 10.1056/NEJMoa2107038 false true Reference 65850307 /api/reference/65850307 70. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28., DOI: 10.1056/NEJMoa1504720 70 10.1056/NEJMoa1504720 false true Reference 65850308 /api/reference/65850308 71. Shah T, Zhang Z, Shah H, Fanaroff AC, Nathan AS, Parise H, et al. Effect of sodium-glucose cotransporter-2 inhibitors on the progression of aortic stenosis. JACC Cardiovasc Interv. 2025;18:738–48., DOI: 10.1016/j.jcin.2024.11.036 71 10.1016/j.jcin.2024.11.036 false true Reference 65850309 /api/reference/65850309 72. Saito Y, Kobayashi Y, Tsujita K, Kuwahara K, Ikari Y, Tsutsui H, et al. Pharmacological and device-based intervention for preventing heart failure after acute myocardial infarction—a clinical review—. Circ J. 2024;88:1727–36., DOI: 10.1253/circj.CJ-24-0633 72 10.1253/circj.CJ-24-0633 false true Reference 65850310 /api/reference/65850310 73. Matsukawa R, Kabu K, Koga E, Hara A, Kisanuki H, Sada M, et al. Optimizing guideline-directed medical therapy during hospitalization improves prognosis in patients with worsening heart failure requiring readmissions. Circ J. 2024;88:1416–24., DOI: 10.1253/circj.CJ-24-0265 73 10.1253/circj.CJ-24-0265 false true Reference 65850311 /api/reference/65850311 74. Tanaka A, Kinugawa K, Kuwahara K, Ito H, Murohara T, Hirata KI, et al. Recommendation for appropriate use of sodium glucose cotransporter 2 inhibitors in treatment of heart failure. Circ J. 2023;87:1707–9., DOI: 10.1253/circj.CJ-23-0605 74 10.1253/circj.CJ-23-0605 false true Reference 65850312 /api/reference/65850312 75. Lindman BR, Pibarot P, Arnold SV, Suri RM, McAndrew TC, Maniar HS, et al. Transcatheter versus surgical aortic valve replacement in patients with diabetes and severe aortic stenosis at high risk for surgery: an analysis of the PARTNER trial (placement of aortic transcatheter valve). J Am Coll Cardiol. 2014;63:1090–9., DOI: 10.1016/j.jacc.2013.10.057 75 10.1016/j.jacc.2013.10.057 false true Reference 65850313 /api/reference/65850313 76. Study Details| A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient’s Calcific Aortic Valve Disease with Mild to Moderate Aortic Stenosis (EVOID-AS)| ClinicalTrials.gov [Internet]. [cited 2025 Feb 11]. Available from: https://clinicaltrials.gov/study/NCT05143177#more-information 76 false true Reference 65850314 /api/reference/65850314 77. Zou P, Guo M, Hu J. Evogliptin for the treatment option for type 2 diabetes: an update of the literature. Expert Rev Clin Pharmacol. 2022;15:747–57., DOI: 10.1080/17512433.2022.2100348 77 10.1080/17512433.2022.2100348 false true Reference 65850315 /api/reference/65850315 78. Cuijpers I, Papageorgiou AP, Carai P, Herwig M, Mügge A, Klein T, et al. Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation. J Cell Mol Med. 2021;25:729–41., DOI: 10.1111/jcmm.16122 78 10.1111/jcmm.16122 false true Reference 65850316 /api/reference/65850316 79. Hamdani N, Hervent AS, Vandekerckhove L, Matheeussen V, Demolder M, Baerts L, et al. Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. Cardiovasc Res. 2014;104:423–31., DOI: 10.1093/cvr/cvu223 79 10.1093/cvr/cvu223 false true /api/publication/36144825 Herwig Melissa et al. Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features. (2025) CARDIOVASCULAR DIABETOLOGY 1475-2840 1475-2840 24 1<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Herwig Melissa </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Sieme Marcel </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10091976"><a href="/gui2/?type=authors&mode=browse&sel=10091976" target="_blank">Kovács Andrea (<span class="authorship-author-name">Kovács Andrea</span> <span class="authorAux-mtmt"> hisztológia, immunológia, kardiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Khan Muchtiar </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Mügge Andreas </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Schmidt Wolfgang E. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Elci Ferhat </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10091267"><a href="/gui2/?type=authors&mode=browse&sel=10091267" target="_blank">Sasidharan Shan (<span class="authorship-author-name">Sasidharan Shan</span> <span class="authorAux-mtmt"> farmakologia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM- SE Kardiovaszkuláris Komorbiditások Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Haldenwang Peter </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Wintrich Jan </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Sasko Benjamin </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Akin Ibrahim </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Domokos Máthé </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Paneni Francesco </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >El-Battrawy Ibrahim </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10028393"><a href="/gui2/?type=authors&mode=browse&sel=10028393" target="_blank">Varga Zoltán V. (<span class="authorship-author-name">Varga Zoltán</span> <span class="authorAux-mtmt"> kardiovaszkuláris kutatás</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Saraiva Francisca </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Leite-Moreira Adelino F. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10010125"><a href="/gui2/?type=authors&mode=browse&sel=10010125" target="_blank">Ferdinandy Péter (<span class="authorship-author-name">Ferdinandy Péter</span> <span class="authorAux-mtmt"> Farmakológia, molekuláris medicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >van Heerebeek Loek </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Falcão-Pires Inês </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10086357"><a href="/gui2/?type=authors&mode=browse&sel=10086357" target="_blank">Hamdani Nazha ✉ (<span class="authorship-author-name">Hamdani Nazha</span> <span class="authorAux-mtmt"> Medicine</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM- SE Kardiovaszkuláris Komorbiditások Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36144825" target="_blank">Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features</a></div> <div> <span class="journal-title">CARDIOVASCULAR DIABETOLOGY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1475-2840">1475-2840</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1475-2840">1475-2840</a>)</span>: <span class="journal-volume">24</span> <span class="journal-issue">1</span> <span class="page"> Paper 203. 20 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1186/s12933-025-02748-y" target="_blank" href="https://doi.org/10.1186/s12933-025-02748-y"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001487788300001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001487788300001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105004922757" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105004922757"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="40361188" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40361188&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="https://cardiab.biomedcentral.com/articles/10.1186/s12933-025-02748-y" target="_blank" href="https://cardiab.biomedcentral.com/articles/10.1186/s12933-025-02748-y"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cardiology and Cardiovascular Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Endocrinology, Diabetes and Metabolism&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Internal Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 16</span> | Független: 14 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 16 | Scopus jelölt:&nbsp;14 | WoS/Scopus jelölt:&nbsp;16 | DOI jelölt:&nbsp;16 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36144825&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 29 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36144825</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> National Research, Development and Innovation Office (NKFIH) of Hungary(FK134751), (TKP2021-EGA), Nemzeti Kardiovaszkuláris Laboratórium(RRF-2.3.1-21-2022-00003) Támogató: NKFIH </div> <div class="lastModified">Utolsó módosítás: 2026.01.19. 10:48 Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) </div> </div></div>